CDR-Life has formed a successful partnership with Boehringer Ingelheim, bringing together our antibody fragment expertise with Boehringer’s clinical development and marketing expertise. Boehringer Ingelheim has announced the intention to move the program forward into Phase 2 clinical testing.
We are open to partnering with companies, academic collaborators and individuals who share our vision and can help bring CDR-Life’s innovations to patients. Our unique M-gager® platform can deliver attractive clinical candidates in a matter of months, which provides an excellent basis for R&D collaborations on novel targets.
Our team has a substantial track record in both forming and working in partnerships between pharma and biotech companies to bring new therapeutics to market for patients.
«Partnering with CDR-Life provides Boehringer Ingelheim with the opportunity to collaborate with a team that has a proven track record developing antibody fragment-based therapeutics…»
Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research, Boehringer Ingelheim
Contact us for partnering opportunities:
sarah.holland@cdr-life.com
AACR Annual Meeting 2025, April 25-30, 2025, in Chicago, Illinois
Swiss Biotech Day 2025, May 5-6, 2025, in Basel, Switzerland
BioEquity 2025, May 12-14, 2025, in Bruges, Belgium
ASCO Annual Meeting 2025, May 30 - June 3, 2025, in Chicago, IL
Jefferies Global Healthcare Conference, June 3-5, 2025, in New York, New York